8 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Novel therapeutic approaches for the treatment of cystic fibrosis based on small molecule transmembrane anion transporters (TAT-CF)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2018,
This project will develop an innovative therapeutic approach for the treatment of Cystic Fibrosis (CF). This condition originates from the defective function of the CFTR protein, a chloride and bicarbonate permeable transmembrane channel. This project will evaluate small molecules capable of facilitating the transmembrane transport of anions such as chloride and bicarbonate and will thus enable CF ...
Voir le projet
8
Participants partenaires
TERMINÉ
Patient-specific stem cell-derived models for Alzheimer’s disease and related neurodegenerative disorders (STEMMAD)
Date du début: 1 févr. 2013, Date de fin: 31 déc. 2017,
Future treatment of incurable neurodegenerative disorders, including Alzheimer’s disease (AD), frontotemporal dementia (FTD), spinocerebellar ataxia (SCA), and Huntington’s disease (HD), has to be tailored to individual patients or cohorts of patients to obtain an optimal effect. The STEMMAD project is aimed to create a highly innovative international collaboration between 2 R&D intensive SME and ...
Voir le projet
5
Participants partenaires
TERMINÉ
Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets (COMPACT)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,
Most biopharmaceuticals (BP) currently on the market are recombinant proteins which are parenterally administered. These would benefit from more patient-friendly routes of administration. Moreover, new classes of BP (e.g. siRNA, miRNA, DARPins) with specificity for intracellular targets hold promise but await the advent of efficient delivery systems before their potential can be realised into ther ...
Voir le projet
22
Participants partenaires
TERMINÉ
Identification and validation of novel pharmaceutical drug targets for cardiovascular disease (CARTARDIS)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,
"Cardiovascular disease (CVD) is one of the major diseases in Europe and the Western world, killing over 2 million people per year in Europe alone and is the foremost cause of premature mortality and disability-adjusted life years, representing an annual economic cost of ∼€ 192 billion in direct and indirect healthcare expenses. The available therapies are insufficient to fulfill the need. The int ...
Voir le projet
13
Participants partenaires
TERMINÉ
The European non-coding RNA network (RNATRAIN)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,
"Non-coding RNA (ncRNA) is a new research field in rapid development. It holds the potential to explain many fundamental biological phenomena and there is a vast prospective for the development of ncRNA-derived diagnostic and therapeutic tools. Hence, biotech and pharmaceutical companies are actively looking into this unexplored territory for novel targets. Therefore, there is a substantial and un ...
Voir le projet
11
Participants partenaires
TERMINÉ
European Bank for induced pluripotent Stem Cells (EBISC)
Date du début: 1 janv. 2014, Date de fin: 31 déc. 2016,
EBiSC is designed to address the increasing demand by iPSC researchers for quality-controlled, disease-relevant research grade iPSC lines, data and cell services. Its goal is to demonstrate an operational banking and distribution service of iPSC lines after 3 years and to establish subsequently for Europe a centralised, not-for-profit bank providing all qualified users with access to scalable, cos ...
Voir le projet
30
Participants partenaires
TERMINÉ
EUROpean consortium on NEUTralising antibodies using gp41 (EURONEUT-41)
Date du début: 1 janv. 2008, Date de fin: 31 mars 2014,
There is now an increasingly solid body of scientific evidence which demonstrates that the binding of small molecular weight compounds, peptides and antibodies (Abs) to fusion-intermediate conformations of gp41 leads to an inhibition of HIV cell entry. The principal aim of this project is to exploit this information by establishing a platform where gp41-derived vaccine candidates will be designed ...
Voir le projet
19
Participants partenaires
TERMINÉ
Biochemically Equivalent Substitutive Technology for Stem Cells (BEST-Stem cells)
Date du début: 1 juil. 2009, Date de fin: 31 déc. 2012,
Current technology to control embryonic and adult stem cell behaviour is dependent on conventional in vitro culture systems and crude factors such as serum and purified proteins, often sourced from vertebrate animal tissue. These factors contribute to variations in cell properties and differentiation potential which impact on the efficacy of cell culture. More worryingly these factors are potentia ...
Voir le projet